Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Mallinckrodt Plc (MNK)

Mallinckrodt Plc (MNK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives PR Newswire - Tue Sep 1, 6:30AM CDT

Month long campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren 's contracture, and connect patients with appropriate care

MNK : 0.3402 (-14.97%)
Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe PR Newswire - Thu Aug 20, 6:30AM CDT

DUBLIN , Aug. 20, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that the first patient has been successfully enrolled and received study treatment in its Phase 3 clinical trial evaluating...

MNK : 0.3402 (-14.97%)
Keenova Reports Second Quarter 2026 Financial Results PR Newswire - Tue Aug 11, 5:30AM CDT

Strong Performance Driven by Growth in Acthar ® Gel 1  and XIAFLEX ® 2

MNK : 0.3402 (-14.97%)
Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology PR Newswire - Mon Aug 3, 6:30AM CDT

DUBLIN , Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's...

MNK : 0.3402 (-14.97%)
Keenova Therapeutics to Report Second Quarter 2026 Financial Results on August 11, 2026 PR Newswire - Thu Jul 30, 6:00AM CDT

DUBLIN , July 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc , a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial...

MNK : 0.3402 (-14.97%)
Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research PR Newswire - Mon Jul 13, 6:30AM CDT

DUBLIN , July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe...

MNK : 0.3402 (-14.97%)
Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis PR Newswire - Wed Jul 8, 6:00AM CDT

DUBLIN , July 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum) for the treatment...

MNK : 0.3402 (-14.97%)
Keenova Champions Men's Health Month with Education and Outreach PR Newswire - Mon Jun 1, 3:15PM CDT

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

MNK : 0.3402 (-14.97%)
Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting PR Newswire - Fri May 15, 6:36AM CDT

DUBLIN , May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX ®...

MNK : 0.3402 (-14.97%)
Keenova Reports First Quarter 2026 Financial Results PR Newswire - Tue May 12, 5:30AM CDT

Strong First-Quarter Performance Driven by Acthar ® Gel 1  and XIAFLEX ® 2

MNK : 0.3402 (-14.97%)

Barchart Exclusives

3 Top Dividend Stocks to Buy in September Barchart - Tue Sep 1, 6:30PM CDT
Chevron, Realty Income, and NextEra bring more than just yield to the table. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.